Kymera Therapeutics KYMR Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's retained earnings?
- Kymera Therapeutics (KYMR) reported retained earnings of -$1.14B in Q1 2026.
- How has Kymera Therapeutics's retained earnings changed year-over-year?
- Kymera Therapeutics's retained earnings decreased by 38.4% year-over-year, from -$820.19M to -$1.14B.
- What is the long-term trend for Kymera Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Kymera Therapeutics's retained earnings has grown at a 52.6% compound annual growth rate (CAGR), from -$128.77M to -$1.07B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.